Therapeutic Asset Ratings
8,586 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Ari-0001
B-cell Adult Acute Lymphoblastic Leukemia
GUSTAVO SALGUERO
P1/2
B
(58)
Ari-0001
B-Cell Lymphoma, Unspecified
Zhujiang Hospital
P1/2
B
(58)
Calcium folinate pentahydrate
Esophageal Cancer
Merck Sharp & Dohme LLC
P1/2
B
(58)
Calcium folinate pentahydrate
Renal Cell Carcinoma
Neonc Technologies, Inc.
P1/2
B
(58)
Carfilzomib
Advanced Lung Non-Small Cell Carcinoma
City of Hope Medical Center
P1/2
B
(58)
cd19-ucart
T Cell Non-Hodgkin Lymphoma
Beijing GoBroad Hospital
P1/2
B
(58)
cd22 car-transduced t cells
B Cell Lymphoma
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
P1/2
B
(58)
Decitabine
Aggressive B-cell Lymphoma
National Cancer Institute (NCI)
P1/2
B
(58)
Docetaxel
Advanced Gastric Adenocarcinoma
Kyowa Kirin Co., Ltd.
P1/2
B
(58)
Fludarabine
SCLC, Extensive Stage
National Cancer Institute (NCI)
P1/2
B
(58)
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER
Gastroesophageal Junction Adenocarcinoma
Merck Sharp & Dohme LLC
P1/2
B
(58)
Ipilimumab
Gastric or Gastroesophageal Junction Adenocarcinoma
Memorial Sloan Kettering Cancer Center
P1/2
B
(58)
Ipilimumab
Recurrent Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
P1/2
B
(58)
Pembrolizumab
Intrahepatic Cholangiocarcinoma
Shanghai 6th People's Hospital
P1/2
B
(58)
Pembrolizumab
Tumor, Solid
Salubris Biotherapeutics Inc
P1/2
B
(58)
Sorafenib
Refractory Malignant Solid Neoplasm
St. Jude Children's Research Hospital
P1/2
B
(58)
Tocilizumab
B-cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
P1/2
B
(58)
(+)-VINCRISTINE
Refractory Malignant Neoplasm
M.D. Anderson Cancer Center
P1/2
B
(58)
VINCRISTINE SULFATE
Plasmablastic Lymphoma
National Cancer Institute (NCI)
P1/2
B
(58)
Acalabrutinib
Part1: Advanced B-cell Malignancies
AstraZeneca
P1/2
B
(57)
Anti-Cd19/Cd22 Car-T Cells
Acute Lymphobkastic Leukemia
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
P1/2
B
(57)
Aptoll
Stroke
aptaTargets S.L.
P1/2
B
(57)
Azacitidine
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
M.D. Anderson Cancer Center
P1/2
B
(57)
Azacitidine
Essential Thrombocythemia
M.D. Anderson Cancer Center
P1/2
B
(57)
Azacitidine
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
M.D. Anderson Cancer Center
P1/2
B
(57)
Showing 76 to 100 of 8,586 assets
Previous
Page 4 of 344
Next